[CAS NO. 213261-59-7] RITA

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [213261-59-7]

Catelog

HY-13424

Brand

MCE

CAS

213261-59-7

DESCRIPTION [213261-59-7]

Overview

MDL	MFCD03235294
Molecular Weight	292.37
Molecular Formula	C14H12O3S2
SMILES	OCC1=CC=C(C2=CC=C(C3=CC=C(CO)S3)O2)S1

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

RITA is an inhibitor of p53-HDM-2 interaction , binds to p53dN, with a K _d of 1.5 nM, and also induces DNA-DNA cross-links .

IC50 & Target

Kd: 1.5 nM (p53dN) ^[1]
DNA Crosslinker ^[2]

In Vitro

RITA inhibits p53-HDM-2 interaction, binding to p53dN, with a K _d of 1.5 nM. RITA (10 μM) blocks complex formation between p53 and HDM-2 in HCT116 cells and HDFs and in NHF-ERMyc cells irrespective of c-Myc expression. RITA (0.5 μM) reduces the viability of tumor cells in a wild-type p53-dependent manner. Moreover, RITA (0.1 μM) induces p53-dependent apoptosis. RITA induces p53 but does not via DNA damage-signaling pathway ^[1] . RITA (NSC 652287) induces DNA-DNA cross-links. RITA induces G2-M cell cycle arrest at 10 nM and causes apoptosis at 100 nM. RITA (100 nM) also elevates p53 and causes dose-dependent effects on p ^21WAF1 protein levels ^[2] . RITA inhibits the growth of HeLa and CaSki cells, with IC ₅₀ s of 1 and 10 μM. In addition, RITA (1 μM) stabilizes p53 by inhibiting p53/E6AP interaction ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

RITA (0.1, 1 or 10 mg/kg, i.p.) shows potent antitumor activity in SCID mice bearing HCT116 and HCT116 TP53 ^−/− xenografts ^[1] . RITA (10 mg/kg, i.p.) also suppresses the growth of HeLa cells in SCID mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05260203	Advice Pharma Group srl	Multiple Myeloma\|Solitary Plasmacytoma\|Amyloidosis\|Chronic Myeloid Leukemia\|Chronic Lymphocytic Leukemia\|T Cell Non-Hodgkin Lymphoma\|Lymphocytic Lymphoma\|Hodgkin Lymphoma\|B-cell Non Hodgkin Lymphoma\|Acute Myeloid Leukemia\|Myelodysplasia\|Chronic Myeloproliferative Disorder\|Treatment Adherence\|Treatment Adherence and Compliance	June 4, 2022	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 342.03 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4203 mL	17.1016 mL	34.2032 mL
5 mM	0.6841 mL	3.4203 mL	6.8406 mL
10 mM	0.3420 mL	1.7102 mL	3.4203 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

2-Thiophenemethanol, 5,5′-(2,5-furandiyl)bis-

5,5′-(2,5-Furandiyl)bis[2-thiophenemethanol]

NSC 652287

RITA

[Furan-2,5-diylbis(thiene-5,2-diyl)]dimethanol

[5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol